Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

NCT00477594 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Lipid Metabolism, Inborn Errors
Hypercholesterolemia, Autosomal Dominant
Hyperlipidemias
Metabolic Diseases
Hyperlipoproteinemia Type II
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Metabolic Disorder
Congenital Abnormalities
Hypercholesterolemia
Hyperlipoproteinemias
Dyslipidemias
Lipid Metabolism Disorders

Interventions

DRUG: mipomersen sodium

Sponsor

Kastle Therapeutics, LLC

Collaborators

[object Object]